Modified Titanium Implant as a Gateway to the Human Body: The Implant Mediated Drug Delivery System

Abstract

The aim of this study was to investigate the efficacy of a proposed new implant mediated drug delivery system (IMDDS) in rabbits. The drug delivery system is applied through a modified titanium implant that is configured to be implanted into bone. The implant is hollow and has multiple microholes that can continuously deliver therapeutic agents into the systematic body. To examine the efficacy and feasibility of the IMDDS, we investigated the pharmacokinetic behavior of dexamethasone in plasma after a single dose was delivered via the modified implant placed in the rabbit tibia. After measuring the plasma concentration, the areas under the curve showed that the IMDDS provided a sustained release for a relatively long period. The result suggests that the IMDDS can deliver a sustained release of certain drug components with a high bioavailability. Accordingly, the IMDDS may provide the basis for a novel approach to treating patients with chronic diseases.

Smart Electrospun Nanofibers for Controlled Drug Release: Recent Advances and New Perspectives

“…Nanoparticles are highly maneuverable and they are often administered via injection [176–179]. The response is fast but frequent injections (e.g., insulin for diabetes) compromise the appliance of patients [180]. Also, nanoparticles lacks the capability in forming a scaffold to support the tissue regeneration.…”

Use of anodized titanium alloy as drug carrier: Ibuprofen as model of drug releasing

“…The potential use of different biomaterials as drug carriers, aimed to the local treatment of many conditions, has been analysed in many reports, aiming to obtain the ideal "intelligent material" (Brohede et al, 2009;Johnson and Garcia, 2014;Park et al, 2014;Przekora et al, 2014;Vallet-Regi et al, 2007;Vallet-Regi and Ruiz-Hernandez, 2011).…”

Plasma concentration of metformin and dexamethasone after administration through Osseogate

“…However, a great deal remains to be learned about the attributes of the Osseogate, the novel route of administration. Although the results of previous studies demonstrated sustained plasma concentrations of a target drug for up to eight weeks (Park et al, 2014a), it is possible that this was due to the unique properties of the drug being evaluated. Therefore, there is a need for continued evaluation of the Osseogate delivery patterns of several drugs with different physicochemical characteristics.…”